Aclarion (NASDAQ:ACON – Get Free Report) and National Research (NASDAQ:NRC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Risk & Volatility
Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
Valuation and Earnings
This table compares Aclarion and National Research”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclarion | $80,000.00 | 44.01 | -$7.23 million | ($5.41) | -0.23 |
| National Research | $137.39 million | 3.89 | $11.60 million | $0.28 | 89.86 |
National Research has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
7.5% of Aclarion shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 9.2% of National Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Aclarion and National Research’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclarion | -10,215.15% | -62.91% | -59.33% |
| National Research | 4.48% | 313.25% | 14.32% |
Analyst Ratings
This is a summary of recent ratings and price targets for Aclarion and National Research, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
| National Research | 0 | 2 | 1 | 0 | 2.33 |
Aclarion presently has a consensus price target of $7.50, suggesting a potential upside of 513.55%. National Research has a consensus price target of $27.00, suggesting a potential upside of 7.31%. Given Aclarion’s higher probable upside, research analysts plainly believe Aclarion is more favorable than National Research.
Summary
National Research beats Aclarion on 10 of the 13 factors compared between the two stocks.
About Aclarion
Aclarion is a healthcare technology company that develops tools to help physicians assess chronic low back pain. Its Nociscan platform combines magnetic resonance spectroscopy data with proprietary biomarkers and software analysis to help identify lumbar discs that may be contributing to a patient’s pain. Nociscan is designed to complement standard MRI by providing additional information about disc chemistry. The company’s technology is intended to support clinical decision-making and help physicians evaluate treatment options; it does not replace a physician’s diagnosis or judgment.
About National Research
National Research Corporation, which operates as NRC Health, provides experience-management and consumer-insights services to organizations in the health care industry. Its research and technology help clients understand how patients, health care consumers and employees perceive their services. The company’s offerings include patient and consumer surveys, employee-engagement research, reputation measurement, analytics and related advisory services. Hospitals, health systems and other health care organizations use these tools to identify opportunities to improve service and strengthen relationships with the communities they serve.
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
